% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sharma:302796,
      author       = {R. Sharma and S. N. Alharbi and K. Ellum and L.
                      Motedayen-Aval and A. Casadei-Gardini and D. J. Pinato and
                      D. Bettinger and B. Bengsch$^*$ and R. Patel and J. Evans},
      title        = {{D}eep sequencing of circulating tumour {DNA} as a
                      biomarker of clinical outcome to transarterial
                      chemoembolisation in hepatocellular carcinoma.},
      journal      = {npj precision oncology},
      volume       = {9},
      number       = {1},
      issn         = {2397-768X},
      address      = {[London]},
      publisher    = {Springer Nature},
      reportid     = {DKFZ-2025-01336},
      pages        = {214},
      year         = {2025},
      abstract     = {Survival following transarterial chemoembolisation (TACE)
                      for hepatocellular cancer (HCC) is variable. We explored
                      targeted sequencing of circulating tumour DNA (ctDNA) as a
                      prognostic biomarker. Plasma samples (n = 97) were collected
                      at baseline and following TACE. Targeted, ultra-deep
                      sequencing was conducted on 18 somatic mutations related to
                      the molecular pathogenesis of HCC. Median progression-free
                      survival and overall survival were 11.6 months $(95\%$ CI:
                      5.83-21.2) and 34 months $(95\%$ CI: 22.35-45.60),
                      respectively. CTNNB1 and ARID1A were the most frequently
                      mutated genes, present in $25\%$ of baseline circulating
                      samples, followed by SF3B1 $(20\%)$ and TERT $(18\%).$ The
                      presence of mutations in CTNNB1, TP53 ARID1A, and KEAP1
                      predicted for poor OS on univariable analysis. Findings
                      suggest that ctDNA profiling of known genetic drivers of HCC
                      may serve as a valuable prognostic biomarker prior to TACE
                      and may assist with the stratification of patients following
                      further evaluation in larger studies.},
      cin          = {FR01},
      ddc          = {610},
      cid          = {I:(DE-He78)FR01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40596669},
      pmc          = {pmc:PMC12218101},
      doi          = {10.1038/s41698-025-00961-2},
      url          = {https://inrepo02.dkfz.de/record/302796},
}